| Drug name | Exenatide |
|---|---|
| Phase | Phase II |
| Indication | Type 2 diabetes |
| Route of administration | Subcutaneous |
| Dosing | 5μg twice a day for one month to improve/test tolerability and then increasing to 10 μg twice a day based on clinical response. |
| Chemical structure | 39-amino acid peptide with a 53% homology to human GLP-1 |
| Clinical trials | Most of the clinical trials have shown a suppressive effect on appetite with a reduction of 3–6 kg of weight and improvement in metabolic and cardiovascular risk factors in non-diabetic patients. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.